ENDPOINTS NEWS1h
Scor­pi­on de­tails ear­ly da­ta on tar­get­ed breast can­cer drug as it seeks to chal­lenge No­var­tis, Roche
BARCELONA — In a first test of Scor­pi­on Ther­a­peu­tics’ ther­a­py for breast can­cer and oth­er sol­id tu­mors, a small ...
ENDPOINTS NEWS1d
In­cyte gears up to face FDA once again with more Zynyz da­ta in rare anal can­cer
Incyte said it has positive late-phase results for its PD-1 drug Zynyz in certain patients with squamous cell carcinoma, ...
ENDPOINTS NEWS1d
GSK, iTeos re­ju­ve­nate strug­gling TIG­IT space with pos­i­tive Phase 2 Jem­per­li com­bo da­ta in lung can­cer
GSK and iTeos have unveiled positive mid-phase data for their PD-1 plus TIGIT doublet in certain lung cancer patients, ...
ENDPOINTS NEWS1d
Nu­va­tion Bio to head to FDA with pooled ROS1-pos­i­tive lung can­cer da­ta
Nuvation Bio outlined pooled data from its two Phase 2 studies at the annual European Society for Medical Oncology confab in ...
ENDPOINTS NEWS2d
Doug Williams re­turns with a ‘FIT’ bet on CAR-Ts; Bio­gen ap­points Mene Pan­ga­los to board
Industry veteran Doug Williams is back with a new approach to CAR-T cell therapies that he expects to take into the clinic in ...
ENDPOINTS NEWS1d
SEC probe of Il­lu­mi­na’s Grail deal tar­gets sales fore­casts, sources say
The SEC’s investigation into the $8 billion deal between Grail and Illumina is examining sales forecasts made by Grail’s ...
ENDPOINTS NEWS2d
FDA ap­proves sub­cu­ta­neous Ocre­vus, broad­en­ing ac­cess to Roche and Genen­tech block­buster
The FDA on Friday approved a new formulation of Roche and Genentech’s multiple sclerosis drug Ocrevus in what they hope will ...
ENDPOINTS NEWS1d
Post-Hoc: Big promis­es built Mod­er­na. They might al­so be its un­do­ing
One of my distinct memories of the early pandemic was sitting in Moderna CEO Stéphane Bancel’s office in Cambridge, MA, as he ...
ENDPOINTS NEWS2d
Au­rinia re­struc­tures board, bring­ing in Kevin Tang and keep­ing CEO
Aurinia Pharmaceuticals offered an olive branch to a group of shareholders clamoring for change. It's shrinking its board by ...
ENDPOINTS NEWS1d
Ad­comm says In­ter­cep­t's rare liv­er dis­ease drug should not get full ap­proval
An FDA advisory committee recommended against full approval for Alfasigma and Intercept Pharmaceuticals’ rare liver disease ...
ENDPOINTS NEWS2d
Atea's poly­merase in­hibitor fails in late-stage Covid-19 treat­ment tri­al
Viral disease-focused biotech Atea Pharmaceuticals announced a late-stage trial failure for its nucleotide polymerase ...
ENDPOINTS NEWS1d
Af­ter a huge IPO and ac­qui­si­tion, Zymer­gen caps off bank­rupt­cy with $30M SEC penal­ty
The rise and fall of the short-lived biotech Zymergen has ended with a $30 million penalty from the SEC. Zymergen's rise ...